BiotechTube

Repatha

ApprovedTerminated
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ischemic Stroke

Conditions

Ischemic Stroke

Trial Timeline

Apr 23, 2021 → Dec 16, 2021

NCT ID
NCT04573777

About Repatha

Repatha is a approved stage product being developed by Amgen for Ischemic Stroke. The current trial status is terminated. This product is registered under clinical trial identifier NCT04573777. Target conditions include Ischemic Stroke.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04573777ApprovedTerminated

Competing Products

20 competing products in Ischemic Stroke

See all competitors
ProductCompanyStageHype Score
Aspirin, ClopidogrelYuhanPre-clinical
23
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
41
DS-1040b + AspirinDaiichi SankyoPhase 1
33
DS1040b + PlaceboDaiichi SankyoPre-clinical
23
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
52
RegadenosonAstellas PharmaPhase 1
33
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
52
RegadenosonAstellas PharmaApproved
85
ASP2246Astellas PharmaPhase 1/2
41
Gadolinium + AdenosineAstellas PharmaPhase 2/3
65
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
52
Redasemtide + PlaceboShionogiPhase 2
52
StatinShionogiApproved
85
fospropofol + propofolEisaiPhase 2
52
PDE5 InhibitorsEli LillyPre-clinical
23
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
52
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
52
Elezanumab + PlaceboAbbViePhase 2
52
Balovaptan + PlaceboRochePhase 2
52
GS-6615 + PlaceboGilead SciencesPhase 1
32

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84